vanoxerine has been researched along with Aura in 1 studies
vanoxerine: structure given in first source
vanoxerine : An N-alkylpiperazine that consists of piperazine bearing 2-bis(4-fluorophenyl)methoxy]ethyl and 3-phenylpropyl groups at positions 1 and 4 respectively. Potent, competitive inhibitor of dopamine uptake (Ki = 1 nM for inhibition of striatal dopamine uptake). Has > 100-fold lower affinity for the noradrenalin and 5-HT uptake carriers. Also a potent sigma ligand (IC50 = 48 nM). Centrally active following systemic administration.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldsmith, P | 1 |
| Golder, Z | 1 |
| Hunt, J | 1 |
| Berghmans, S | 1 |
| Jones, D | 1 |
| Stables, JP | 1 |
| Murphree, L | 1 |
| Howden, D | 1 |
| Newton, PE | 1 |
| Richards, FM | 1 |
1 other study available for vanoxerine and Aura
| Article | Year |
|---|---|
GBR12909 possesses anticonvulsant activity in zebrafish and rodent models of generalized epilepsy but cardiac ion channel effects limit its clinical utility.
Topics: Animals; Anticonvulsants; Arrhythmias, Cardiac; Dogs; Dopamine Uptake Inhibitors; Electrocardiograph | 2007 |